Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-06-23 EDT			5-day change	1st Jan Change
179,000 ^KRW	+1.07%		-0.44%	-11.17%

06-17	Celltrion Reveals Positive Phase III Results of Rheumatoid Arthritis Drug	MT
06-14	Celltrion, Inc. announces an Equity Buyback for 410,734 shares.	CI

Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on April 17, 2024.

June 04, 2024 at 03:04 am

From April 17, 2024 to May 31, 2024, the company has repurchased 436,047 shares, representing 0.21% for KRW 80,550.32 million. With this, the company has completed the repurchase of 436,047 shares, representing 0.21% for KRW 80,550.32 million under the buyback announced on April 17, 2024.

Latest news about Celltrion, Inc.

Celltrion Reveals Positive Phase III Results of Rheumatoid Arthritis Drug	06-17	MT
Celltrion, Inc. announces an Equity Buyback for 410,734 shares.	06-13	CI
Celltrion Showcases Promising Results in Phase III study for CT-P47, A Biosimilar Candidate of Roactemra® (Tocilizumab) in Patients with Rheumatoid Arthritis (RA) at EULAR 2024	06-13	CI
Celltrion, Inc. authorizes a Buyback Plan.	06-13	CI
Celltrion's Avastin Biosimilar Gains 12% Market Share in Japan	06-07	MT
AbbVie's tight grip on Humira market raises concerns about biosimilars	06-07	RE
Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on April 17, 2024.	06-04	CI
Celltrion, Inc.'s Equity Buyback announced on April 17, 2024, has closed with 436,047 shares, representing 0.21% for KRW 80,550.32 million.	05-30	CI
Celltrion Receives European Commission Approval of Omlyclo® (CT-P39), the First and Only Omalizumab Biosimilar Approved in Europe	05-23	CI
Celltrion, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-16	CI
Celltrion's Q1 Attributable Profit Slumps 86%	05-10	MT
Market Share of Celltrion’s Remsima Rises to 74% in Europe	04-24	MT
Celltrion, Inc. announces an Equity Buyback for 436,047 shares.	04-17	CI
Celltrion, Inc. authorizes a Buyback Plan.	04-16	CI
Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on March 5, 2024.	03-28	CI
Celltrion, Inc.'s Equity Buyback announced on March 5, 2024, has closed with 425,895 shares, representing 0.21% for KRW 78,072.21 million.	03-25	CI
Celltrion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-18	CI
South Korean Shares Close Higher on Tech Gains; Celltrion Shares Add 1% on Zymfentra Launch in the US	03-18	MT
Celltrion's Autoimmune Disease Treatment Hits US Markets	03-18	MT
South Korean Shares Slightly Slip as Investors Seek Cues on Future Rate Direction from US Fed	03-06	MT
Celltrion Announces 75 Billion Won Share Buyback Plan	03-06	MT
Celltrion, Inc. announces an Equity Buyback for 425,895 shares.	03-04	CI
Celltrion, Inc. authorizes a Buyback Plan.	03-04	CI
South Korean Shares Dip on Tech, Pharma Losses; Celltrion Sheds 5% on Lackluster Q4 Earnings	02-29	MT
Celltrion's Net Profit Nosedives 98.5% in Q4 2023 as Revenue Declines 25%	02-29	MT

Chart Celltrion, Inc.

Duration

Period

More charts

Company Profile

Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.

Sector

Biotechnology & Medical Research

Calendar

2024-11-10 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Celltrion, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

178,400 KRW

Average target price

231,375 KRW

Spread / Average Target

+29.69%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CELLTRION, INC.	-11.17%	26.39B
MODERNA, INC.	+38.36%	52.73B
LONZA GROUP AG	+38.68%	39B
IQVIA HOLDINGS INC.	-8.63%	38.52B
ALNYLAM PHARMACEUTICALS, INC.	+25.46%	30.38B
ICON PUBLIC LIMITED COMPANY	+11.44%	26.08B
UNITED THERAPEUTICS CORPORATION	+45.09%	14.15B
MEDPACE HOLDINGS, INC.	+32.93%	12.6B
BIO-TECHNE CORPORATION	-5.30%	11.51B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-12.69%	10.63B

Other Biotechnology & Medical Research